

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07K 7/06, 7/08, 14/47, A61K 38/04</b>		<b>A2</b>	(11) International Publication Number: <b>WO 99/60016</b>
			(43) International Publication Date: 25 November 1999 (25.11.99)
(21) International Application Number: <b>PCT/CA99/00414</b>			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 20 May 1999 (20.05.99)			
(30) Priority Data: 09/082,420 20 May 1998 (20.05.98) US			
(71) Applicant: UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; 2194 Health Science Mall, Vancouver, British Columbia V6T 1Z3 (CA).			
(72) Inventors: HANCOCK, Robert, E. W.; 3505 West 32nd Avenue, Vancouver, British Columbia V6S 1Z1 (CA). WU, Manhong; 2731 Fairview Crescent, Vancouver, British Columbia V6T 2B8 (CA).			
(74) Agent: MBM & CO.; P.O. Box 809, Station B, Ottawa, Ontario K1P 5P9 (CA).			Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: <b>ANTIMICROBIAL CATIONIC PEPTIDE DERIVATIVES OF BACTENECIN</b>			
(57) Abstract  A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## ANTIMICROBIAL CATIONIC PEPTIDE DERIVATIVES OF BACTENECIN

### BACKGROUND OF THE INVENTION

#### 1. *Field of the Invention*

This invention relates generally to antimicrobial peptides and specifically to derivatives of  
5 the antimicrobial cationic peptide, bactenecin.

#### 2. *Description of Related Art*

In 1981, the self-promoted uptake hypothesis was first proposed to explain the mechanism  
of action of polycationic antibiotics in *Pseudomonas aeruginosa*. According to this  
hypothesis, polycations interact with sites on the outer membranes of Gram-negative bacteria  
10 at which divalent cations cross-bridge adjacent lipopolysaccharide molecules. Due to their  
higher affinity for these sites, polycations displace the divalent cations and, since the  
polycations are bulkier than the divalent cations, cause structural perturbations in the outer  
membrane. These perturbations result in increased outer membrane permeability to  
compounds such as the  $\beta$ -lactam antibiotic nitrocefin, the eukaryotic non-specific defense  
15 protein lysozyme and to hydrophobic substances. By analogy, molecules accessing this  
pathway are proposed to promote their own uptake.

It has been clearly demonstrated that the outer membranes of Gram-negative bacteria are  
semipermeable molecular "sieves" which restrict access of antibiotics and host defense  
molecules to their targets within the bacterial cell. Thus, cations and polycations which  
20 access the self-promoted uptake system are, by virtue of their ability to interact with and  
break down the outer membrane permeability barrier, capable of increasing the susceptibility  
of Gram-negative pathogenic bacteria to antibiotics and host defense molecules. Hancock  
and Wong demonstrated that a broad range of such compounds could overcome the  
permeability barrier and coined the name "permeabilizers" to describe them (Hancock and  
25 Wong, *Antimicrob. Agents Chemother.*, 26:48, 1984). While self-promoted uptake and  
permeabilizers were first described for *P. aeruginosa*, they have now been described for a  
variety of Gram-negative bacteria.

Over the past decade, non-specific defense molecules have been described in many animals, including insects and humans. One subset of these molecules have in common the following features: (a) they are small peptides, usually 15-35 amino acids in length, (b) they contain 4 or more positively charged amino acid residues, either lysines or arginines, and (c) they are found in high abundance in the organisms from which they derive. Several of these molecules have been isolated, amino acid sequenced and described in the patent literature (e.g., cecropins: WO8900199, WO 8805826, WO8604356, WO 8805826; defensins: EP 193351, EP 85250, EP 162161, US 4659692, WO 8911291). However, only limited amounts of these peptides can be isolated from the host species. For example, Sawyer, *et al.*, (*Infect. Immun.* 56:693, 1988) isolated 100-200 mg of rabbit neutrophil defensins 1 and 2 from 10<sup>9</sup> primed peritoneal neutrophils or lipopolysaccharide-elicited alveolar macrophages (*i.e.*, the numbers present in a whole animal).

The gene for human defensin has been cloned and sequenced, but no successful expression has been demonstrated, as yet. Furthermore, production of these peptides using peptide synthesis technology produces peptides in limited amounts and is expensive when scaled up or when many variant peptides must be produced. Also, structural analysis is difficult without specific incorporation of <sup>15</sup>N and <sup>13</sup>C tagged amino acids which is prohibitively expensive using amino acid synthesis technology.

Recently, cationic peptides containing a disulphide bond forming a looped structure were identified (Morikawa *et al.*, *Biochim. Biophys. Res. Commun.* 189:184, 1992; Simmaco *et al.*, *FEBS* 324:159, 1993; Clark *et al.*, *J. Biol. Chem.* 269:10849, 1994). One member of this group, batenecin (*i.e.*, dodecapeptide), is a twelve amino acid peptide isolated from bovine neutrophils (Romeo *et al.*, *J. Biol. Chem.* 263:9573, 1988). Batenecin is the smallest known cationic antimicrobial peptide. Two cysteine residues form a disulphide bond to make batenecin a loop molecule. Batenecin was previously found to be active against *Escherichia coli* and *Staphylococcus aureus*, and strongly cytotoxic for rat embryonic neurons, fetal rat astrocytes and human glioblastoma cells (Radermacher *et al.*, *J. Neuroscience Res.* 36:657, 1993).

There is a need to develop peptides having a broad range of potent antimicrobial activity against a plurality of microorganisms, including gram negative bacteria, gram positive bacteria, fungi, protozoa, viruses and the like. To that end, the small size and structure of bactenecin present an opportunity to identify derivatives of the polypeptide which are effective as therapeutics for microbial pathogens.

### SUMMARY OF THE INVENTION

The present invention provides derivatives of the antimicrobial cationic peptide bactenecin, that have antimicrobial activity. In a first embodiment, the invention provides antimicrobial peptides derived from bactenecin. Exemplary peptides include: RLCRIVVIRVCR (SEQ ID NO:1); RLARIVVIRVAR (SEQ ID NO:2); RLSRIVVIRVCR (SEQ ID NO:3); RLSRIVVIRVSR (SEQ ID NO:4); RRCPIVVIRVCR (SEQ ID NO:5); RICRIVVIRCIR (SEQ ID NO:6); RLCPRVIRVCR (SEQ ID NO:7); KKCPVVIRVCK (SEQ ID NO:8); RRCPIVVIRVCRR (SEQ ID NO:9); RRRLCPIVVIRVCRR (SEQ ID NO:10); RRLCRIVVIRVCRR (SEQ ID NO:11); RLCRIVPVIRVCR (SEQ ID NO:12); RLCRIVWVIRVCR (SEQ ID NO:13); RRLCRIVWVIRVCRR (SEQ ID NO:14); RRCPIVWVIRVCR (SEQ ID NO:15); RRCPIVWVIPVCRR (SEQ ID NO:16); RLCRIVVIRVCR (SEQ ID NO:17); and RLCRIVVIRVCRIVIVIV (SEQ ID NO:18), and analogs, derivatives, amidated variations and conservative variations thereof.

The invention also provides a method of inhibiting the growth of bacteria including contacting the bacteria with an inhibiting effective amount of at least one peptide of the invention alone, or in combination with at least antibiotic. Classes of antibiotics that can be used in synergistic therapy with the peptides of the invention include aminoglycoside, penicillin, cephalosporine, fluoroquinolone, carbapenem, tetracycline and macrolide.

The invention further provides polynucleotides that encode the peptides of the invention. Exemplary polynucleotides encode peptides including: RLCRIVVIRVCR (SEQ ID NO:1); RLARIVVIRVAR (SEQ ID NO:2); RLSRIVVIRVCR (SEQ ID NO:3); RLSRIVVIRVSR (SEQ ID NO:4); RRCPIVVIRVCR (SEQ ID NO:5); RICRIVVIRCIR (SEQ ID NO:6);

RLCPRVIRVCR (SEQ ID NO:7); KKCPIVVIRVCK (SEQ ID NO:8);  
RRRCPIVVIRVCRR (SEQ ID NO:9); RRRLCPIVVIRVCRR (SEQ ID NO:10);  
RRLCRIVVIRVCRR (SEQ ID NO:11); RLCRIVPVIRVCR (SEQ ID NO:12);  
RLCRIVWVIRVCR (SEQ ID NO:13); RRLCRIVWVIRVCRR (SEQ ID NO:14);  
5 RRCPIVWVIRVCR (SEQ ID NO:15); RRCPIVWVIPVCRR (SEQ ID NO:16);  
RLCRIVVIRVCR (SEQ ID NO:17); and RLCRIVVIRVCRIVIVIV (SEQ ID NO:18), and  
analogs, derivatives and conservative variations thereof.

In another embodiment, the invention provides a method of inhibiting an endotoxemia or  
sepsis associated disorder in a subject having or at risk of having such a disorder, by  
10 administering to the subject a therapeutically effective amount of at least one peptide of the  
invention.

The invention also provides a method of inhibiting the growth of a eukaryotic cell. The  
method includes contacting the cell with an inhibiting effective amount of a peptide or  
combination thereof of the invention, alone, or in combination with an agent effective for  
15 inhibiting eukaryotic cell growth. Classes of such agents which can be used for synergistic  
therapy with the peptides of the invention include bleomycin, neocarzinostatin, suramin,  
doxorubicin, taxol, mitomycin C and cisplatin.

The invention further provides a method of inhibiting a cell proliferation-associated disorder  
in a subject having or at risk of having such a disorder. The method includes administering  
20 to the subject a therapeutically effective amount of at least one peptide of the invention,  
alone, or in combination with an agent effective for inhibiting eukaryotic cell growth.  
Classes of such agents which can be used for synergistic therapy with the peptides of the  
invention include bleomycin, neocarzinostatin, suramin, doxorubicin, taxol, mitomycin C  
and cisplatin.

### BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows the CD spectra of battenecin in its reduced form and bac2S in phosphate buffer, in the presence POPC/POPG liposomes, in 60% TFE and in 10mM SDS. The concentrations of peptides and liposomes were 50 mM and 100 mM, respectively. CD measurements were taken in 10 mM sodium phosphate buffer (pH 7.0) in the absence (panel A) and the presence (panel B) of POPC/POPG. Panel C shows the spectra in the presence of 60% (v/v) TFE. Battenecin: .....; Reduced battenecin: \_\_\_\_; Bac2S: - - - .

FIGURE 1A shows the CD spectra of battenecin in 10 mM sodium phosphate buffer (pH 7.0) in the absence of POPC/POPG.

FIGURE 1B shows the CD spectra of battenecin in 10 mM sodium phosphate buffer (pH 7.0) in the presence of POPC/POPG.

FIGURE 1C shows the CD spectra of battenecin in 10 mM sodium phosphate buffer (pH 7.0) in the presence of 60% (v/v) TFE.

FIGURE 2 shows a graph of the binding of peptides to LPS as assessed by their ability to displace dansyl polymyxin B from *E. coli* UB1005 LPS. Dansyl-polymyxin B was added to 1ml of 3 mg/ml LPS to a final concentration of 1mM which saturated the binding sites on LPS, and the fluorescence sensitivity was adjusted to 90%. The peptides and Mg<sup>2+</sup> were titrated in resulting in a decrease in fluorescence due to dansyl polymyxin displacement until no decrease or very small decrease was detected. Polymyxin B: -x-; MgCl<sub>2</sub>: -\*; Battenecin: -Δ-; Bac2S -■-; Battenecin (reduced): -●-.

FIGURE 3 shows peptide-induced outer membrane permeabilization measured by the NPN uptake in *E. coli* UB1005. Mid-log phase *E. coli* cells were collected and incubated with NPN in the presence of various concentrations of battenecin (oxidized), bac2S, battenecin (reduced). NPN was taken up into cells when the outer membrane was disrupted by the

peptides. The uptake of NPN was measured by the increase of fluorescence. Polymyxin B: -□-; Bactenecin: -+-; Bac2S: -o-; Bactenecin (Reduced): -▽-

FIGURE 4 shows the effect of peptide-induced inner membrane permeabilization measured by the DiS-C3-(5) assay. Mid-log phase cells were collected and resuspended in buffer  
5 (5mM HEPE, 5mM glucose) so that OD600=0.05. 0.2 mM final concentration of DiS-C3-(5) were incubated with cell suspension until no more quench was detected, then 0.1M KCL was added. Desired peptide concentration was added to 1 cm cuvette containing 1 ml cell suspension. The fluorescence change was observed until the equilibrium was reached. The fluorescence were taken as arbitrary units. MIC concentrations were indicated by arrows.  
10 Polymyxin: -□-; Bactenecin: -+-; Bac2S: -Δ-; Bactenecin(reduced): -○-.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides derivatives of bactenecin, an antimicrobial cationic peptide, which have antimicrobial activity. These peptides are useful for inhibiting microbial infection or growth, as well reducing the effects of endotoxemia, and are often synergistic  
15 with conventional antibiotics and/or lysozyme. In addition, such peptides are useful as antifungal agents, antitumor agents, or antiviral agents.

The term "antimicrobial" as used herein means that the peptides of the present invention inhibit, prevent, or destroy the growth or proliferation of microbes such as bacteria, fungi, viruses, parasites or the like. The term "antiviral" as used herein means that the peptides of  
20 the present invention inhibit, prevent or destroy the growth or proliferation of viruses or of virally-infected cells. The term "anti-tumor" as used herein means that the peptides of the present invention may be used to inhibit the growth of or destroy tumors. The term "antifungal" as used herein means that the peptides of the present invention may be used to inhibit the growth of or destroy fungi. The term "antiparasite", as used herein, means that  
25 the peptides of the present invention inhibit, prevent, or destroy the growth or proliferation of any organism that lives at the expense of a host organism.

In a first embodiment, the invention provides an isolated antimicrobial peptide derived from bactenecin. Exemplary peptides of the invention have an amino acid sequence including: RLCRIVVIRVCR (SEQ ID NO:1); RLARIVVIRVAR (SEQ ID NO:2); RLSRIVVIRVCR (SEQ ID NO:3); RLSRIVVIRVSR (SEQ ID NO:4); RRCPIVVIRVCR (SEQ ID NO:5);  
5 RICRIVVIRCIR (SEQ ID NO:6); RLCPRVIRVCR (SEQ ID NO:7); KKCPIVVIRVCK (SEQ ID NO:8); RRRCPVVIRVCRR (SEQ ID NO:9); RRRLCPIVVIRVCRR (SEQ ID NO:10); RRLCRIVVIRVCRR (SEQ ID NO:11); RLCRIVPVIRVCR (SEQ ID NO:12); RLCRIVWVIRVCR (SEQ ID NO:13); RRLCRIVWVIRVCRR (SEQ ID NO:14); RRCPIVWVIRVCR (SEQ ID NO:15); RRCPIVWVIPVCRR (SEQ ID NO:16);  
10 RLCRIVVIRVCR (SEQ ID NO:17); and RLCRIVVIRVCRIVIVIV (SEQ ID NO:18), and analogs, derivatives, amidated variations and conservative variations thereof, wherein the peptides have antimicrobial activity. The peptides of the invention include SEQ ID NOS:1-18, as well as the broader groups of peptides having hydrophilic and hydrophobic substitutions, and conservative variations thereof.

15 The term "isolated" as used herein refers to a peptide substantially free of proteins, lipids, nucleic acids, for example, with which it is naturally associated. Those of skill in the art can make similar substitutions to achieve peptides with greater antimicrobial activity and a broader host range. For example, the invention includes the bactenecin derivative peptides depicted in SEQ ID NO:1-18, as well as analogues or derivatives thereof, as long as the  
20 bioactivity (*e.g.*, antimicrobial) of the peptide remains. Minor modifications of the primary amino acid sequence of the peptides of the invention may result in peptides which have substantially equivalent activity as compared to the specific peptides described herein. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the peptides produced by these modifications are included herein as long as the  
25 biological activity of the original peptide still exists.

Further, deletion of one or more amino acids can also result in a modification of the structure of the resultant molecule without significantly altering its biological activity. This can lead to the development of a smaller active molecule which would also have utility. For example,

amino or carboxy terminal amino acids which may not be required for biological activity of the particular peptide can be removed. Peptides of the invention include any analog, homolog, mutant, isomer or derivative of the peptides disclosed in the present invention, so long as the bioactivity as described herein is remains. All peptides were synthesized using  
5 L amino acids, however, all D forms of the peptides (*e.g.*, see Table 1) can be synthetically produced. In addition, C-terminal derivatives can be produced, such as C-terminal methyl esters and C-terminal amidates (*e.g.*, see table I), in order to increase the antimicrobial activity of a peptide of the invention.

“Peptide” of the invention includes peptides which are conservative variations of those  
10 peptides specifically exemplified herein. The term “conservative variation” as used herein denotes the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine, alanine, cysteine, glycine, phenylalanine, proline, tryptophan, tyrosine, norleucine or methionine for another, or the substitution of one polar  
15 residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, and the like. Neutral hydrophilic amino acids which can be substituted for one another include asparagine, glutamine, serine and threonine. The term “conservative variation” also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted  
20 polypeptide also immunoreact with the unsubstituted polypeptide. Such conservative substitutions are within the definition of the classes of the peptides of the invention.

The biological activity of the peptides can be determined by standard methods known to those of skill in the art, such as “minimal inhibitory concentration (MIC)” assay described in the present examples, whereby the lowest concentration at which no change in OD is  
25 observed for a given period of time is recorded as MIC. Alternatively, “fractional inhibitory concentration (FIC)” is also useful for determination of synergy between the peptides of the invention, or the peptides in combination with known antibiotics. FICs are performed by checkerboard titrations of peptides in one dimension of a microtiter plate, and of antibiotics

in the other dimension, for example. The FIC is calculated by looking at the impact of one antibiotic on the MIC of the other and vice versa. An FIC of one indicates that the influence of the compounds is additive and an FIC of less than one indicates synergy. Preferably, an FIC of less than 0.5 is obtained for synergism. As used herein, FIC can be determined as

5 follows:

$$\text{FIC} = \frac{\text{MIC (peptide in combination)}}{\text{MIC (peptide alone)}} + \frac{\text{MIC (antibiotic in combination)}}{\text{MIC (antibiotic alone)}}$$

Peptides of the invention can be synthesized by such commonly used methods as t-BOC or FMOC protection of alpha-amino groups. Both methods involve stepwise syntheses  
10 whereby a single amino acid is added at each step starting from the C terminus of the peptide (See, Coligan, *et al.*, *Current Protocols in Immunology*, Wiley Interscience, 1991, Unit 9). Peptides of the invention can also be synthesized by the well known solid phase peptide synthesis methods described Merrifield, *J. Am. Chem. Soc.*, 85:2149, 1962), and Stewart and Young, *Solid Phase Peptides Synthesis*, (Freeman, San Francisco, 1969, pp.27-62), using a  
15 copoly(styrene-divinylbenzene) containing 0.1-1.0 mMol amines/g polymer. On completion of chemical synthesis, the peptides can be deprotected and cleaved from the polymer by treatment with liquid HF-10% anisole for about 1/4-1 hours at 0°C. After evaporation of the reagents, the peptides are extracted from the polymer with 1% acetic acid solution which is then lyophilized to yield the crude material. This can normally be purified by such  
20 techniques as gel filtration on Sephadex G-15 using 5% acetic acid as a solvent. Lyophilization of appropriate fractions of the column will yield the homogeneous peptide or peptide derivatives, which can then be characterized by such standard techniques as amino acid analysis, thin layer chromatography, high performance liquid chromatography, ultraviolet absorption spectroscopy, molar rotation, solubility, and quantitated by the solid  
25 phase Edman degradation.

The invention includes polynucleotides encoding peptides of the invention. Exemplary polynucleotides encode peptides including: RLCRIVVIRVCR (SEQ ID NO:1);

RLARIVVIRVAR (SEQ ID NO:2); RLSRIVVIRVCR (SEQ ID NO:3); RLSRIVVIRVSR (SEQ ID NO:4); RRCPIVVIRVCR (SEQ ID NO:5); RICRIVVIRCIR (SEQ ID NO:6); RLCPRVIRVCR (SEQ ID NO:7); KKCPIVVIRVCK (SEQ ID NO:8); RRRCPVVIRVCRR (SEQ ID NO:9); RRRLCPIVIRVCRR (SEQ ID NO:10);  
5 RRLCRIVVIRVCRR (SEQ ID NO:11); RLCRIVPVIRVCR (SEQ ID NO:12); RLCRIVWVIRVCR (SEQ ID NO:13); RRLCRIVWVIRVCRR (SEQ ID NO:14); RRCPIVWVIRVCR (SEQ ID NO:15); RRCPIVWVIPVCRR (SEQ ID NO:16); RLCRIVVIRVCR (SEQ ID NO:17); and RLCRIVVIRVCRIVIVIV (SEQ ID NO:18), and analogs, derivatives, amidated variations and conservative variations thereof, wherein the  
10 peptides have antimicrobial activity. The peptides of the invention include SEQ ID NOS:1-18, as well as the broader groups of peptides having hydrophilic and hydrophobic substitutions, and conservative variations thereof.

The term "isolated" as used herein refers to a polynucleotide substantially free of proteins, lipids, nucleic acids, for example, with which it is naturally associated. As used herein,  
15 "polynucleotide" refers to a polymer of deoxyribonucleotides or ribonucleotides, in the form of a separate fragment or as a component of a larger construct. DNA encoding a peptide of the invention can be assembled from cDNA fragments or from oligonucleotides which provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit. Polynucleotide sequences of the invention include DNA, RNA and  
20 cDNA sequences. A polynucleotide sequence can be deduced from the genetic code, however, the degeneracy of the code must be taken into account. Polynucleotides of the invention include sequences which are degenerate as a result of the genetic code. Such polynucleotides are useful for the recombinant production of large quantities of a peptide of interest, such as the peptide of SEQ ID NO:1-18.

25 In the present invention, the polynucleotides encoding the cationic peptides of the invention may be inserted into a recombinant "expression vector". The term "expression vector" refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of cationic genetic sequences. Such expression vectors of the

invention are preferably plasmids which contain a promoter sequence which facilitates the efficient transcription of the inserted genetic sequence in the host.

The expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells. For example, the  
5 expression of the peptides of the invention can be placed under control of *E. coli* chromosomal DNA comprising a lactose or lac operon which mediates lactose utilization by elaborating the enzyme beta-galactosidase. The lac control system can be induced by IPTG. A plasmid can be constructed to contain the *lac Iq* repressor gene, permitting repression of the *lac* promoter until IPTG is added. Other promoter systems known in the art include beta  
10 lactamase, lambda promoters, the protein A promoter, and the tryptophan promoter systems. While these are the most commonly used, other microbial promoters, both inducible and constitutive, can be utilized as well. The vector contains a replicon site and control sequences which are derived from species compatible with the host cell. In addition, the vector may carry specific gene(s) which are capable of providing phenotypic selection in  
15 transformed cells. For example, the beta-lactamase gene confers ampicillin resistance to those transformed cells containing the vector with the beta-lactamase gene. An exemplary expression system for production of the peptides of the invention is described in U.S. Patent No. 5,707,855.

Transformation of a host cell with the polynucleotide may be carried out by conventional  
20 techniques well known to those skilled in the art. For example, where the host is prokaryotic, such as *E. coli*, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth and subsequently treated by the  $\text{CaCl}_2$  method using procedures well known in the art. Alternatively,  $\text{MgCl}_2$  or  $\text{RbCl}$  could be used.

25 In addition to conventional chemical methods of transformation, the plasmid vectors of the invention may be introduced into a host cell by physical means, such as by electroporation or microinjection. Electroporation allows transfer of the vector by high voltage electric

impulse, which creates pores in the plasma membrane of the host and is performed according to methods well known in the art. Additionally, cloned DNA can be introduced into host cells by protoplast fusion, using methods well known in the art.

DNA sequences encoding the cationic peptides can be expressed *in vivo* by DNA transfer  
5 into a suitable host cell. "Host cells" of the invention are those in which a vector can be propagated and its DNA expressed. The term also includes any progeny of the subject host cell. It is understood that not all progeny are identical to the parental cell, since there may be mutations that occur during replication. However, such progeny are included when the terms above are used. Preferred host cells of the invention include *E. coli*, *S. aureus* and *P.*  
10 *aeruginosa*, although other Gram-negative and Gram-positive organisms known in the art can be utilized as long as the expression vectors contain an origin of replication to permit expression in the host.

The cationic peptide polynucleotide sequence used according to the method of the invention can be isolated from an organism or synthesized in the laboratory. Specific DNA sequences  
15 encoding the cationic peptide of interest can be obtained by: 1) isolation of a double-stranded DNA sequence from the genomic DNA; 2) chemical manufacture of a DNA sequence to provide the necessary codons for the cationic peptide of interest; and 3) *in vitro* synthesis of a double-stranded DNA sequence by reverse transcription of mRNA isolated from a donor cell. In the latter case, a double-stranded DNA complement of mRNA is eventually formed  
20 which is generally referred to as cDNA.

The synthesis of DNA sequences is frequently the method of choice when the entire sequence of amino acid residues of the desired peptide product is known. In the present invention, the synthesis of a DNA sequence has the advantage of allowing the incorporation of codons which are more likely to be recognized by a bacterial host, thereby permitting high  
25 level expression without difficulties in translation. In addition, virtually any peptide can be synthesized, including those encoding natural cationic peptides, variants of the same, or synthetic peptides.

When the entire sequence of the desired peptide is not known, the direct synthesis of DNA sequences is not possible and the method of choice is the formation of cDNA sequences. Among the standard procedures for isolating cDNA sequences of interest is the formation of plasmid or phage containing cDNA libraries which are derived from reverse transcription  
5 of mRNA which is abundant in donor cells that have a high level of genetic expression. When used in combination with polymerase chain reaction technology, even rare expression products can be cloned. In those cases where significant portions of the amino acid sequence of the cationic peptide are known, the production of labeled single or double-stranded DNA or RNA probe sequences duplicating a sequence putatively present in the target cDNA may  
10 be employed in DNA/DNA hybridization procedures which are carried out on cloned copies of the cDNA which have been denatured into a single stranded form (Jay, *et al.*, *Nuc. Acid Res.*, 11:2325, 1983).

The invention also provides a method of inhibiting the growth of bacteria including contacting the bacteria with an inhibiting effective amount of a peptide of the invention,  
15 including:RLCRIVVIRVCR (SEQ ID NO:1); RLARIVVIRVAR (SEQ ID NO:2); RLSRIVVIRVCR (SEQ ID NO:3); RLSRIVVIRVSR (SEQ ID NO:4); RRCPIVIRVCR (SEQ ID NO:5); RICRIVVIRCIR (SEQ ID NO:6); RLCPRVIRVCR (SEQ ID NO:7); KKCPIVIRVCK (SEQ ID NO:8); RRCPIVIRVCRR (SEQ ID NO:9); RRRLCPIVIRVCRR (SEQ ID NO:10); RRLCRIVVIRVCRR (SEQ ID NO:11);  
20 RLCRIVPVIRVCR (SEQ ID NO:12); RLCRIVWVIRVCR (SEQ ID NO:13); RRLCRIVWVIRVCRR (SEQ ID NO:14); RRCPIVWVIRVCR (SEQ ID NO:15); RRCPIVWVIPVCRR (SEQ ID NO:16); RLCRIVVIRVCR (SEQ ID NO:17); and RLCRIVVIRVCRIVIVIV (SEQ ID NO:18), and analogs, derivatives, amidated variations and conservative variations thereof, wherein the peptides have antimicrobial activity.

25 The term "contacting" refers to exposing the bacteria to the peptide so that the peptide can effectively inhibit, kill, or lyse bacteria, bind endotoxin (LPS), or permeabilize gram-negative bacterial outer membranes. Contacting may be *in vitro*, for example by adding the peptide to a bacterial culture to test for susceptibility of the bacteria to the peptide.

Contacting may be *in vivo*, for example administering the peptide to a subject with a bacterial disorder, such as septic shock. "Inhibiting" or "inhibiting effective amount" refers to the amount of peptide which is required to cause a bacteriostatic or bactericidal effect. Examples of bacteria which may be inhibited include *Escherichia coli*, *Pseudomonas a-*  
5 *eruginosa*, *Enterobacter cloacae*, *Staphylococcus typhimurium*, *Staphylococcus aureus*, *Enterobacter faecalis*, *Listeria monocytogenes*, *Corynebacterium xerosis*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Streptococcus mitis* and *Staphylococcus epidermidis*.

The method of inhibiting the growth of bacteria may further include the addition of antibiotics for combination or synergistic therapy. The appropriate antibiotic administered  
10 will typically depend on the susceptibility of the bacteria such as whether the bacteria is gram negative or gram positive, and will be easily discernable by one of skill in the art. Examples of particular classes of antibiotics useful for synergistic therapy with the peptides of the invention include aminoglycosides (e.g., tobramycin), penicillins (e.g., piperacillin), cephalosporins (e.g., ceftazidime), fluoroquinolones (e.g., ciprofloxacin), carbapenems (e.g.,  
15 imipenem), tetracyclines and macrolides (e.g., erythromycin and clarithromycin). The method of inhibiting the growth of bacteria may further include the addition of antibiotics for combination or synergistic therapy. The appropriate antibiotic administered will typically depend on the susceptibility of the bacteria such as whether the bacteria is gram negative or gram positive, and will be easily discernable by one of skill in the art. Further  
20 to the antibiotics listed above, typical antibiotics include aminoglycosides (amikacin, gentamicin, kanamycin, netilmicin, tobramycin, streptomycin, azithromycin, clarithromycin, erythromycin, erythromycin estolate/ethylsuccinate/gluceptate/lactobionate/stearate), beta-lactams such as penicillins (e.g., penicillin G, penicillin V, methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, ampicillin, amoxicillin, ticarcillin, carbenicillin, mezlocillin,  
25 azlocillin and piperacillin), or cephalosporins (e.g., cephalothin, cefazolin, cefaclor, cefamandole, cefoxitin, cefuroxime, cefonicid, cefmetazole, cefotetan, cefprozil, loracarbef, cefetamet, cefoperazone, cefotaxime, ceftizoxime, ceftriaxone, ceftazidime, cefepime, cefixime, cefpodoxime, and cefsulodin). Other classes of antibiotics include carbapenems (e.g., imipenem), monobactams (e.g., aztreonam), quinolones (e.g., fleroxacin, nalidixic acid,

norfloxacin, ciprofloxacin, ofloxacin, enoxacin, lomefloxacin and cinoxacin), tetracyclines (e.g., doxycycline, minocycline, tetracycline), and glycopeptides (e.g., vancomycin, teicoplanin), for example. Other antibiotics include chloramphenicol, clindamycin, trimethoprim, sulfamethoxazole, nitrofurantoin, rifampin and mupirocin.

- 5 The peptides and/or analogues or derivatives thereof may be administered to any host, including a human or non-human animal, in an amount effective to inhibit not only growth of a bacterium, but also a virus, parasite or fungus. These peptides are useful as antimicrobial agents, antiviral agents, and antifungal agents. The peptides and/or analogues or derivatives thereof may be administered to any host, including a human or non-human animal, in an  
10 amount effective to inhibit not only growth of a bacterium, but also a virus or fungus. These peptides are useful as antimicrobial agents, antiviral agents, and antifungal agents.

- In addition to being active against a broad range of pathogens, bactenecin has been shown to be cytotoxic to rat embryonic neurons, fetal rat astrocytes and human glioblastoma cells (Radermacher *et al.*, *J. Neuro. Res.* 36:657, 1993). Thus, it is envisioned that the bactenecin  
15 derivative peptides of the present invention can be used to inhibit the growth of a eukaryotic cell by contacting the eukaryotic cell with an inhibiting effective amount of a peptide of the invention. Such a method would be useful, for example, for inhibiting a cell proliferation-associated disorder in a subject having or at risk of having such a disorder. The method can involve, for example, administering to the subject a therapeutically effective amount of a  
20 peptide of the present invention to inhibit the over-growth of cells in a subject in need of such treatment. Such disorders would include, for example, neurological related disorders.

- In a further embodiment, the peptides of the invention can be administered in combination with at least one chemotherapeutic agent useful for treating a cell proliferation-associated disorder, such as a neoplastic disorder. Examples of such chemotherapeutic agents include,  
25 but are not limited to, bleomycin, neocarzinostatin, suramin, doxorubicin, taxol, mitomycin C and cisplatin. Such neoplastic disorders would include, for example, neuroblastomas, glioblastomas and astrocytomas.

The peptide of the invention can be administered parenterally by injection or by gradual infusion over time. The peptide can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally. Further methods for delivery of the peptide include orally, by encapsulation in microspheres or proteinoids, by aerosol  
5 delivery to the lungs, or transdermally by iontophoresis or transdermal electroporation. The method of the invention also includes delivery systems such as microencapsulation of peptides into liposomes. Microencapsulation also allows co-entrapment of antimicrobial molecules along with the antigens, so that these molecules, such as antibiotics, may be delivered to a site in need of such treatment in conjunction with the peptides of the  
10 invention. Liposomes in the blood stream are generally taken up by the liver and spleen. Thus, the method of the invention is particularly useful for delivering antimicrobial peptides to such organs. Other methods of administration will be known to those skilled in the art.

Preparations for parenteral administration of a peptide of the invention include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous  
15 solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient  
20 replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.

The invention provides a method of treating or ameliorating an endotoxemia or septic shock (sepsis) associated disorder, or one or more of the symptoms of sepsis comprising  
25 administering to a subject displaying symptoms of sepsis or at risk for developing sepsis, a therapeutically effective amount of a cationic peptide of the invention, for example, SEQ ID NOS:1-18, or analogs, derivatives, amidated variations or conservative variations thereof. The term "ameliorate" refers to a decrease or lessening of the symptoms of the disorder

- being treated. Such symptoms which may be ameliorated include those associated with a transient increase in the blood level of TNF, such as fever, hypotension, neutropenia, leukopenia, thrombocytopenia, disseminated intravascular coagulation, adult respiratory distress syndrome, shock and multiple organ failure. Patients who require such treatment
- 5 include those at risk for or those suffering from toxemia, such as endotoxemia resulting from a gram-negative bacterial infection, venom poisoning, or hepatic failure, for example. In addition, patients having a gram-positive bacterial, viral or fungal infection may display symptoms of sepsis and may benefit from such a therapeutic method as described herein. Those patients who are more particularly able to benefit from the method of the invention
- 10 are those suffering from infection by *Escherichia coli*, *Haemophilus influenza B*, *Neisseria meningitides*, staphylococci, or pneumococci. Patients at risk for sepsis include those suffering from gunshot wounds, renal or hepatic failure, trauma, burns, immunocompromised (HIV), hematopoietic neoplasias, multiple myeloma, Castleman's disease or cardiac myxoma.
- 15 The term "therapeutically effective amount" as used herein for treatment of endotoxemia refers to the amount of cationic peptide used is of sufficient quantity to decrease the subject's response to LPS and decrease the symptoms of sepsis. The term "therapeutically effective" therefore includes that the amount of cationic peptide sufficient to prevent, and preferably reduce by at least 50%, and more preferably sufficient to reduce by 90%, a clinically
- 20 significant increase in the plasma level of TNF. The dosage ranges for the administration of cationic peptide are those large enough to produce the desired effect. Generally, the dosage will vary with the age, condition, sex, and extent of the infection with bacteria or other agent as described above, in the patient and can be determined by one skilled in the art. The dosage can be adjusted by the individual physician in the event of any contraindications.
- 25 In any event, the effectiveness of treatment can be determined by monitoring the level of LPS and TNF in a patient. A decrease in serum LPS and TNF levels should correlate with recovery of the patient.

In addition, patients at risk for or exhibiting the symptoms of sepsis can be treated by the method as described above, further comprising administering, substantially simultaneously with the therapeutic administration of cationic peptide, an inhibitor of TNF, an antibiotic, or both. For example, intervention in the role of TNF in sepsis, either directly or indirectly, such as by use of an anti-TNF antibody and/or a TNF antagonist, can prevent or ameliorate the symptoms of sepsis. Particularly preferred is the use of an anti-TNF antibody as an active ingredient, such as a monoclonal antibody with TNF specificity as described by Tracey, *et al.* (*Nature*, 330:662, 1987).

A patient who exhibits the symptoms of sepsis may be treated with an antibiotic in addition to the treatment with cationic peptide. Typical antibiotics include an aminoglycoside, such as gentamicin or a beta-lactam such as penicillin, or cephalosporin or any of the antibiotics as previously listed above. Therefore, a preferred therapeutic method of the invention includes administering a therapeutically effective amount of cationic peptide substantially simultaneously with administration of a bactericidal amount of an antibiotic. Preferably, administration of cationic peptide occurs within about 48 hours and preferably within about 2-8 hours, and most preferably, substantially concurrently with administration of the antibiotic.

The term "bactericidal amount" as used herein refers to an amount sufficient to achieve a bacteria-killing blood concentration in the patient receiving the treatment. The bactericidal amount of antibiotic generally recognized as safe for administration to a human is well known in the art, and as is known in the art, varies with the specific antibiotic and the type of bacterial infection being treated.

Because of the antibiotic, antimicrobial, and antiviral properties of the peptides, they may also be used as preservatives or sterillants of materials susceptible to microbial or viral contamination. The peptides of the invention can be utilized as broad spectrum antimicrobial agents directed toward various specific applications. Such applications include use of the peptides as preservatives in processed foods (organisms including *Salmonella*,

*Yersinia*, *Shigella*), either alone or in combination with antibacterial food additives such as lysozymes; as a topical agent (*Pseudomonas*, *Streptococcus*) and to kill odor producing microbes (*Micrococci*). The relative effectiveness of the cationic peptides of the invention for the applications described can be readily determined by one of skill in the art by  
5 determining the sensitivity of any organism to one of the peptides.

The following examples are intended to illustrate but not limit the invention. While they are typical of those that might be used, other procedures known to those skilled in the art may alternatively be used.

### EXAMPLE 1

10

#### BACTENECIN DERIVATIVES

Bactenecin was isolated from bovine neutrophils. It has an amino acid sequence of RLCRIVVIRVCR (SEQ ID NO:19), with two cysteine residues forming one disulphide (termed native bactenecin or oxidized bactenecin below), and its C-terminus is unamidated according to the publications presented to date. Moderate activity against three gram-  
15 negative bacteria, *Escherichia coli*, *Pseudomonas aeruginosa* and *Salmonella typhimurium* was observed. A series of derivatives were made (Table I). The bactenecin derivatives were divided into three groups, linear, positive-charge and hydrophobicity.

**Table I: Amino Acid Sequences of Bactenecin and its Derivatives**

Peptide Classification	Name	Amino Acid Sequence	SEQ ID NO:
Native	Bactenecin	RLCRIVVIRVCR	1
Linear	Bac 2A-NH <sub>2</sub>	RLARIVVIRVAR-NH <sub>2</sub>	2
	Bac 1S-NH <sub>2</sub>	RLSRIVVIRVCR-NH <sub>2</sub>	3
	Bac 2S-NH <sub>2</sub>	RLSRIVVIRVSR-NH <sub>2</sub>	4
	Bac 2S	RLSRIVVIRVSR	4
	Bac (Reduced)	RLCRIVVIRVCR	1
5 Positive Charge	Bac R, P-NH <sub>2</sub>	RRCPIVVIRVCR-NH <sub>2</sub>	5
	Bac R, P	RRCPIVVIRVCR	5
	Bac 2I-NH <sub>2</sub>	RICRIVVIRCIR-NH <sub>2</sub>	6
	Bac P, 2R-NH <sub>2</sub>	RLCPRVIRVCR-NH <sub>2</sub>	7
	Bac 3K, P	KKCPVVIRVCK	8
	Bac 3R, P	RRRCPIVVIRVCRR	9
	Bac 3R, P, (V)	RRRLCPIVVIRVCRR	10
	Bac 2R	RRLCRIVVIRVCRR	11
	Hydrophobicity Bac P	RLCRIVPVIRVCR	12
	Bac W	RLCRIVWVIRVCR	13
Others	Bac W, 2R	RRLCRIVWVIRVCRR	14
	Bac R, P, W	RRCPIVWVIRVCR-NH <sub>2</sub>	15
	Bac 2R, 2P, W	RRCPIVWVIPVCRR-NH <sub>2</sub>	16
	Bac-NH <sub>2</sub>	RLCRIVVIRVCR-NH <sub>2</sub>	17
	Bac 3I, 3V	RLCRIVVIRVCRIVIVIV	18

**EXAMPLE 2****MATERIAL AND METHODS****10 Bacterial Strains and Chemicals**

Bacterial strains for antimicrobial activity testing included *Escherichia coli* UB1005 and its antibiotic supersusceptible derivative DC2 (Richmond et al., *Antimicrob. Agents Chemother.* 10:215, 1976), *Pseudomonas aeruginosa* K799 and its antibiotic-supersusceptible derivative Z61 (Angus et al., *Antimicrob. Agents Chemother.* 21:299, 1982), *Salmonella typhimurium* 14028s and its defensin-supersusceptible derivative MS7953s (Fields et al., *Science*, 243:1059, 1989), *Staphylococcus aureus* ATCC25923 and a clinical isolate *Staphylococcus*

*aureus* SAP1007. Other Gram-positive bacterial strains include *Staphylococcus epidermidis* (clinical isolate) and *Enterococcus faecalis* ATCC29212, *Listeria monocytogenes*, *Corynebacterium xerosis*, *Streptococcus pneumoniae* ATTC49619, *Streptococcus pyogenes* ATTC19615, *Streptococcus mitis*.

- 5 Polymyxin B and 1-N-phenylnaphthylamine (NPN) were purchased from Sigma (St. Louis, Mo). 3,3-Dipropylthiacarbocyanine (DiS-C3-(5)) was from Molecular Probes (Eugene, Oregon). Dansyl polymyxin B was synthesized as described previously (Schindler and Teuber, *Antimicrob. Agents Chemother.* 8:94, 1975). The lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-glycerol  
10 (POPG) were purchased from Northern Lipids Inc. (Vancouver, BC, Canada).

#### *Synthesis and refolding of batenecin*

- Batenecin and its linear variant bac2S were synthesized by Fmoc (N-(9-fluorenyl) methoxycarbonyl) chemistry by the Nucleic Acid/Protein Service unit at the University of British Columbia using an Applied Biosystems, Inc. (Foster City, CA) Model 431 peptide  
15 synthesizer. The purchased batenecin was in its fully reduced form. After a series of trials to determine the optimal strategy, the disulphide bond was formed by air-oxidation in 0.01M Tris buffer at room temperature for 24h. The concentration of batenecin was kept below 100 mg/ml in the oxidation buffer to minimize the formation of multimers. A reversed phase column Pep RPC HR5/5 (Pharmacia; Quebec, Canada) was used to purify the disulphide-  
20 bonded batenecin from the multimer by-product. The column was equilibrated with 0.3% (v/v) aqueous trifluoroacetic acid and eluted with a gradient of acetonitrile in 0.3% TFA at a flow rate of 0.7 ml/min. Peptide concentration was determined by amino acid analysis. Matrix-assisted laser desorption/ionization (MALDI)-mass spectrometry and acid-urea PAGE (Spiker, *Anal. Biochem.* 108:263, 1980) were used to confirm that the disulphide  
25 bond was properly formed, and a pure product obtained.

### ***Circular Dichroism***

A Jasco (Japan) J-720 spectropolarimeter was used to measure the circular dichroism spectra (Falla, *J. Biol. Chem.* 271:19298, 1996). The data was collected and analyzed by Jasco software. Liposomes POPC/POPG (7:3) were prepared by the freeze-thaw method to  
5 produce multilamellar vesicles as described previously (Mayer, *Biochim. Biophys. Acta*, 817:193, 1985), followed by extrusion through 0.1mm double stacked Nuclepore filters using an extruder device (Lipex Biomembranes, Vancouver, BC Canada), resulting in unilamellar liposomes. Peptide at a final concentration of 50 mM was added to 100 mM liposomes, and incubated at room temperature for 10 min before the CD measurement.

### 10 ***Antimicrobial Activity***

The minimal inhibitory concentration (MIC) of peptides was determined by a modified two-fold microtitre broth dilution method modified from that of Steinberg et al (Steinberg, *Antimicrob. Agents Chemother.* 41:1738, 1997). Using the classical method (Amsterdam, *Antibiotics in Laboratory Medicine* (Lorian, V., ed) pp. 72-78, 1991), higher concentrations  
15 of peptides tend to precipitate in the LB broth, thus the concentrations of peptides in the sequential wells are not accurate. Also the peptides stick to the most readily available (tissue-culture treated polystyrene) 96-well microtitre plates. Therefore the 2X series of dilutions was performed in Eppendoff tubes (polypropylene) before mixing with LB broth. Serial of two fold dilutions of peptides ranging from 640 mg/ml to 1.25 mg/ml were made  
20 in 0.2% BSA, 0.01% acetic acid buffer in the Eppendoff tubes. Ten ml of each concentration was added to each corresponding well of a 96-well microtiter plate (polypropylene cluster; Costar Corporation, Cambridge, MA). Bacteria were grown overnight and diluted 10<sup>-5</sup> into fresh LB broth or Todd Hewitt broth for *Streptococcus*. LB medium contained 10g/l tryptone and 5g/l yeast extract, with no salt. Todd Hewitt contained 500g/l beef heart  
25 infusion, 20g/l bacto neopeptone, 2g/l bacto dextrose, 2g/l sodium chloride, 0.4g/l disodium phosphate, 2.5g/l sodium carbonate. One hundred ml of broth containing about 10<sup>4</sup>-10<sup>5</sup> CFU/ml of tested bacteria was added to each well. The plate was incubated at 37°C overnight. The MIC was taken as the concentration at which greater than 90% of growth inhibition was observed.

***Dansyl-polymyxin B displacement assay***

E.coli UB1005 LPS was prepared according to the phenol-chloroform-petroleum ether extraction method (Moore *et al.*, *Antimicrob. Agents Chemother.* 29:496, 1986). The dansyl-polymyxin B displacement assay (American Society for Microbiology in *Methods for*  
5 *General Molecular Bacteriology*, pp. 91-92, 1994) was used to determine the relative binding affinity of peptides for LPS.

***Membrane permeabilization assays***

The ability of peptides to permeabilize the outer membrane was determined by the NPN assay of Loh *et al.* (Loh *et al.*, *Antimicrob. Agents Chemother.* 19:777, 1984). Cytoplasmic  
10 membrane permeabilization was determined by using the membrane potential sensitive cyanine dye DiS-C3-(5) (Sims *et al.*, *Biochemistry* 13:3315, 1974). The mutant *E. coli* DC2 with increased outer membrane permeability was used so that DiS-C3-(5) could reach the cytoplasmic membrane. Fresh LB medium was inoculated with an overnight culture, grown at 37°C, and mid-logarithmic phase cells (OD600 = 0.5 - 0.6) were collected. The cells were  
15 washed with buffer (5mM HEPES, pH 7.2, 5mM glucose) once, then resuspended in the same buffer to an OD600 of 0.05. The cell suspension was incubated with 0.2 mM DiS-C3-(5) until DiS-C3-(5) uptake was maximal (as indicated by a stable reduction in fluorescence due to fluorescence quenching as the dye became concentrated in the cell by the membrane potential), and 100mM KCl was added to equilibrate the cytoplasmic and external K+  
20 concentration. One ml cell culture was placed in a 1cm cuvette and desired concentration of tested peptide was added. The fluorescence reading was monitored by using a Perkin-Elmer model 650-10S fluorescence spectrophotometer (Perkin-Elmer Corp. Norwalk, Conn), with an excitation wavelength of 622nm and an emission wavelength of 670nm. The maximal increase of fluorescence due to the disruption of the cytoplasmic membrane by  
25 certain concentration of cationic peptide was recorded. A blank with only cells and the dye was used to subtract the background. Control experiments titrating with valinomycin and K+ showed that the increase in fluorescence was directly proportional to the membrane potential and that a buffer concentration of 100mM KCl prevented any effects of the high internal K+ concentration and corresponding opposing chemical gradient.

### **EXAMPLE 3**

#### **RESULTS**

##### ***Bactenecin and its linear derivatives***

The amino acid sequence of bactenecin and its linear derivatives are shown in Table I. The  
5 linear derivative (bac2S) with two cysteine residues replaced by two serine residues, was  
made to determine the importance of the disulphide bond in bactenecin's antimicrobial  
activity. The reduced form of bactenecin was also included in this study as a linear version  
of bactenecin. The identity of these peptides was confirmed by MALDI mass spectrometry.  
The MALDI data showed the molecular weight of the reduced bactenecin as 1486+1 dalton  
10 and oxidized bactenecin as 1484+1 dalton, in agreement with formation of one disulphide  
bond in the latter.

##### ***Circular Dichroism***

Circular dichroism (CD) spectrometry (Fig. 1A) showed that bactenecin in the reduced form  
and bac2S was present in 10 mM sodium phosphate buffer as an unordered structure which  
15 had a strong negative ellipticity near 200nm. Native bactenecin had a spectrum resembling  
oxyribonuclease and nuclease that are short polypeptides with a disulphide bond (Sims et  
al., *Biochemistry* 13:3315, 1974). The CD spectrum of bactenecin (Fig. 1A), demonstrated  
a negative ellipticity near 205nm, typical of that seen for a type I b-turn structure (*Circular  
Dichroism and the conformational analysis of biomolecules* (Fasman G. D., ed) pp.318,  
20 1996). In 60% TFE buffer, in the presence of liposomes and 10mM SDS, the native  
bactenecin retained a similar structure (Fig. 1B, 1C). However, the reduced form and bac2S  
exhibited clearly distinct structures from those observed in the aqueous solution. In 60%  
TFE buffer (considered an helix-inducing solvent), these two peptides tended to form a-  
helical structure (Fig. 1B), whereas and in the presence of liposomes (or 10mM SDS), a b-  
25 sheet structure was evident (Fig. 1C). SDS micelles resemble the environment of lipid  
membranes.

### ***Antimicrobial Activity***

The MIC of bactenecin and its derivatives against a range of bacteria was determined by using a modified broth dilution method. Derivatives of bactenecin (Table I) were made to study the importance of the disulphide bond, three of them were also amidated at the C-terminal. The reduced forms of all peptides in the other groups were also included as linear derivatives in the minimum inhibitory concentration (MIC) test (Table IIC and IID). The MIC results showed that linearization changed the antimicrobial spectrum, linear derivatives were more active against Gram-positive bacteria than the native bactenecin (Table IIB, IID). The three amidated linear derivatives Bac 2A-NH<sub>2</sub>, Bac S-NH<sub>2</sub>, Bac 2S-NH<sub>2</sub> also retained comparable activities against Gram-negative bacteria (Table IIA) with the native form. Bac 2A-NH<sub>2</sub> was the most active one in this group. Its small size (12 amino acids long) also contributed to its interest as a prospective human antibiotic.

Eight derivatives had either additional positive charges or had the position of their positive charges rearranged. All had similar or better MIC values compared to the native bactenecin against Gram-negative and Gram-positive bacteria (Table IIIB). Three were constructed with 2 added positive charges: several of these derivatives with or without amidated C-terminuses had 4-fold better MICs against E-coli than native bactenecin (Table IIIA). Bac 2R was the best one in this group. Its MIC values against *P. aeruginosa* and *S. typhimurium* were also 2X better than the native bactenecin and it had better Gram positive specific activities.

Three derivatives with hydrophobicity changed were the last group, and the most interesting one. Bac W, Bac W, 2R showed excellent activities against Gram-positive bacteria (Table IVB) while Bac W kept the activities against Gram-negative bacteria, Bac W, 2R also showed good activities against Gram-negative bacteria (Table IVA).

Table V showed the ability of bactenecin and its linear derivatives to lyse human red blood cells. Only Bac (reduced) and Bac W, 2R caused agglutination of human red blood cells at 16-32mg/ml, which is higher than their MIC values. And it seemed that disulphide bond reduced the activity against red blood cells.

- 5 Bac 2A, Bac S-NH<sub>2</sub>, Bac 2S-NH<sub>2</sub>, Bac W and Bac W, 2P showed growth inhibiting activities against some clinically significant bacteria, (e.g., *S. aureus*, *E. faecalis*, *S. pyogenes* and *S. pneumoniae*) whereas Bac 2R and Bac 2R,W were effective antimicrobials vs. clinically-significant Gram negative bacteria.

**Table IIA MIC Values (µg/ml) of Linear (Group1) Bactenecin Derivatives Against**

10

**Gram-Negative Bacteria**

Peptide	<i>E.coli</i> UB1005	<i>P.aeruginosa</i>	<i>S.typhimurium</i>	No. of Positive Charges
Bac 2A-NH <sub>2</sub>	4	8	32	5
Bac S-NH <sub>2</sub>	4	16	>64	5
Bac 2S-NH <sub>2</sub>	2	16	32	5
15 Bac 2S	16 (32)	>64	>64	4
Bac (Reduced)	64	>64	>64	4
Bac (Oxidized)	8	8	8	4

Table IIB MIC Values ( $\mu\text{g/ml}$ ) of Linear Bactenecin Derivatives (Group 1) Against Gram-Positive Bacteria

Peptide	<i>Staph. aureus</i>	<i>Staph. epidermidis</i>	<i>S. E. faecalis</i>	<i>Listeria</i>	<i>C. xerosis</i>	<i>Strep. pyogenes</i>	<i>Strep. mitis</i>	<i>Strep. pneumoniae</i>
Bac 2A-NH2	4	1	2	0.25	0.25	2	0.25	16
Bac S-NH2	16	2	16	0.5	0.5	8	0.5	8
Bac 2S-NH2	4	1	4	0.25	0.25	2	0.125	16
Bac 2S	16	8	8	1	0.5	16	0.5	>64
Bac (Reduced)	>64	8	8	1	1	16	1	4
Bac (Oxidized)	32-64	>64	>64	8	1	16	2	>64

*Listeria* = *Listeria monocytogenes*, *Staph.* = *Staphylococcus*, *E.* = *Enterococcus*, *C.* = *Corynebacterium*, *Strep.* = *Streptococcus*.

Table IIC MIC Values ( $\mu\text{g/ml}$ ) of Linear (Group 2) Bactenecin Derivatives Against Gram-Negative Bacteria

Peptide	<i>E. coli</i> UB1005	<i>P. aeruginosa</i>	<i>S. typhimurium</i>	Length of amino acids	No. of Positive Charges
Bac (Reduced)	64	>64	>64	12	4
Bac 3K, P	>64	>64	>64	12	4(3 K, 1R)
Bac 3R, P	8	>64	>64	14	6
Bac 3R, P, (V)	4	32	32	13	6
Bac P	16	32	64	13	4
Bac W	>64	>64	64	13	4
Bac 2R	4	16	32	14	6
Bac 2R, W	>64	>64	>64	15	6
Bac (Oxidized)	8	8	8	12	4

Table IID MIC Values ( $\mu\text{g/ml}$ ) of Linear (Group 2) Bactenecin Against Gram-Positive Bacteria

Peptide	<i>Staph. aureus</i>	<i>Staph. epidermidis</i>	<i>E. faecalis</i>	<i>Listeria</i>	<i>C. xerosis</i>	<i>Strep. pyogenes</i>	<i>Strep. mitis</i>	<i>Strep. pneumoniae</i>
Bac (Reduced)	>64	8	8	1	1	16	1	4
Bac 3K, P	>64	>64	>64	4	4	64	0.25	>64
Bac 3R, P	>64	16	64	2	0.5	16	0.5	>64
Bac 3R, P, (V)	>64	8	32	1	0.5	8	1	>64
Bac P	>64	16	32	4	2	32	2	>64
Bac W	>64	32	32	2	1	16	1	32
Bac 2R	>64	4	4	0.5	0.25	16	0.5	>64
Bac 2R, W	>64	32	>64	4	2	32	2	64
Bac (Oxidized)	32-64	>64	>64	8	1	16	2	>64

Table IIIA MIC Values ( $\mu\text{g/ml}$ ) of Non-linear (Positive-Charge Modification Derivatives) Bactenecin Derivatives Against Gram-Negative Bacteria

Peptide	<i>E. coli</i> UB1005	<i>P. aeruginosa</i>	<i>S. typhimurium</i>
Bac 3K, P	16	>64	32
Bac 3R, P	2	8	8
Bac 3R, P, (V)	2	8	8
Bac 2R	2	4	4
Bac R, P-NH2	2	16	16
Bac R, P	4	$\geq 32$	16
Bac 2I-NH2	4	16	8
Bac 2R, P-NH2	4	16	32

Bactenecin	8	8	8
------------	---	---	---

Table IIIB MIC Values (µg/ml) of Non-linear (Positive-Charge Modification Derivatives) Bactenecin Derivatives Against Gram-Positive Bacteria

	<i>Staph. aureus epidermidis</i>	<i>Staph. aureus</i>	<i>E. faecalis</i>	<i>Listeria</i>	<i>C. xerosis</i>	<i>Strep. pyogenes</i>	<i>S. S. pneumoniae</i>
Bac 3K, P	>64	>64	>64	8	16	>64	2
Bac 3R, P	>64	16	32	0.5	4	8	1
Bac 3R, P, (V)	>64	16	>64	1	4	4	1
Bac 2R	64	8	32	<0.125	1	8	0.5
Bac R, P-NH2	32-64	32	>64	1	2	16	2
Bac R, P	32	>32	>32	8	16	>64	16
Bac 2I-NH2	32	8	>32	-	-	-	-
Bac 2R, P-NH2	>32	16	>32	-	-	-	-
Bactenecin	32-64	>64	>64	1	8	16	2

Table IVA MIC Values (µg/ml) of Non-linear (Hydrophobicity Modification Derivatives) Bactenecin Derivatives Against Gram-Negative Bacteria.

	<i>E. coli UB1005</i>	MIC (µg/ml) <i>P. aeruginosa</i>	<i>S. typhimurium</i>
Bac P	32	>64	>64
Bac W	8	4	4
Bac 2R, W	2	2	2
Bactenecin	8	8	8

Table IVB MIC Values ( $\mu\text{g/ml}$ ) of Non-Linear (Hydrophobicity Modification Derivatives) Bactenecin Derivatives Against Gram-Positive Bacteria

Peptide	<i>Staph. aureus</i>	<i>Staph. epidermidis</i>	<i>E. faecalis</i>	<i>Listeria</i>	<i>C. xerosis</i>	<i>Strep. pyogenes</i>	<i>S. mitis</i>	<i>S. pneumoniae</i>
Bac P	64	64	>64	2	8	64	4	>64
Bac W	4	2	8	0.5	1	2	1	16
Bac 2R, W	2	1	2	0.25	0.25	1	0.25	8
Bactenecin	32-64	>64	>64	1	8	16	2	>64

Table V Cell agglutinating activities of Bactenecin and its Derivatives on Human Red Blood Cells

Minimal Agglutinating Concentration ( $\mu\text{g/ml}$ )	
Peptide	Reduced Form
Bac 2A-NH <sub>2</sub>	>64
Bac S-NH <sub>2</sub>	>64
5 Bac 2S-NH <sub>2</sub>	>64
Bac 2S	>64
Bactenecin (Reduced)	16
Bac R, P-NH <sub>2</sub>	>64
Bac R, P	>64
10 Bac 3K, P	>64
Bac 3R, P	64
Bac 3R, P, (V)	>64
Bac P	64
Bac W	32
15 Bac 2R	64
Bac 2R, W	32
Bac 2I-NH <sub>2</sub>	32
Bac 2R, P-NH <sub>2</sub>	>32
Bactenecin (Oxidized)	64

### ***Binding of bactenecins to purified E. coli UB1005***

The MIC results indicated that the interaction with the outer membrane might be critical in the difference in antimicrobial activity against Gram negative bacteria among three bactenecin forms. The first step of cationic peptide antimicrobial action has been shown  
5 to involve the binding of the cationic peptide to the negatively charged surface of the target cells (Hancock *et al.*, *Adv. Microb. Physiol.* 37:135, 1995). In Gram negative bacteria, this initial interaction occurs between the cationic peptides and the negatively charged LPS in the outer membrane (Falla *et al.*, *J. Biol. Chem.* 271:19298, 1996; Sawyer *et al.*, *Infect. Immun.* 56:693, 1988; Piers and Hancock, *Mol. Microbio.* 12:951,  
10 1994). Such binding can be quantified using the dansyl polymyxin B displacement assay. Dansyl polymyxin B is a fluorescently tagged cationic lipopeptide, which is non-fluorescent in free solution, but fluoresces strongly when it binds to LPS. When the peptides bind to LPS, they displace dansyl polymyxin B resulting in decreased fluorescence, which can be assessed as a function of peptide concentration (Fig. 2).  
15 Bactenecin was a relatively weak LPS-binder compared to polymyxin B, but it was still better than  $Mg^{2+}$ , the native divalent cation associated with LPS. Most importantly, it seemed that native bactenecin bound to LPS far better than its linear derivative and reduced form, which partially explained the difference in activities against Gram negative bacteria.

### ***Effect on outer membrane permeability***

Antimicrobial peptides bind to LPS, displacing the native divalent cations. Due to their bulky nature they disrupt the outer membrane and self-promote their own uptake across the outer membrane. In order to determine whether better binding ability resulted in better outer membrane permeabilization, a NPN assay was performed. NPN is a neutral  
25 hydrophobic probe that is excluded by an intact outer membrane, but is taken up into the membrane interior of an outer membrane that is disrupted by antimicrobial peptide action. NPN fluoresces weakly in free solution but strongly when it enters the membrane. Fig. 3 showed that polymyxin B permeabilized the outer membrane to 50% of maximal increase in fluorescence arbitrary units at 0.4 mg/ml, while bactenecin, bac2S  
30 and linear bactenecin caused half maximal permeabilization at 0.8 mg/ml, 2 mg/ml and

4.5 mg/ml respectively. Bactenecin was thus better than the linearized derivative and its reduced form at permeabilizing the outer membrane of *E. coli* UB1005.

***Effect on inner membrane potential gradient***

It has been proposed that the antibacterial target of cationic peptides be at the cytoplasmic membrane. Cationic peptides are generally able to interact electrostatically with the negatively charged headgroups of bacterial phospholipids and then insert into the cytoplasmic membrane, forming channels or pores which are proposed to lead to the leakage of cell contents and cell death. However there is very little data for peptides pertaining to measurement of the disruption of the cytoplasmic membrane permeability barrier, despite ample evidence that membrane disruption can occur in model membrane systems. Previous methods have utilized measurements of the accessibility of a normally-membrane-impermeable substrate to cytoplasmic  $\beta$ -galactosidase, this assay suffers from using a bulky substrate (ortho nitrophenyl galactoside). To circumvent this an assay was developed involving the membrane potential sensitive dye diS-C3-(5) to measure the disruption of electrical potential gradients in intact bacteria. The use of the *E. coli* mutant DC2 permitted us to perform this assay in the absence of EDTA. The fluorescent probe diS-C3-(5), which is a caged cation, distributes between cells and medium depending on the cytoplasmic membrane potential. Once inside the cells, diS-C3-(5) becomes concentrated and self-quenches its own fluorescence. If peptides form channels or otherwise disrupt the membrane, the membrane potential will be dissipated, and the DiS-C3-(5) will be released into the medium causing the fluorescence to increase, as can be detected by fluorescent spectrometry. In these assays, 0.1M KCl was added to the buffer to balance the chemical potential of  $K^+$  inside and outside the cells. Therefore the MICs of bactenecin, reduced bactenecin and bac2S in the presence of 0.1M KCl were determined and shown to be 8-16 mg/ml (*i.e.* 4 to 8 fold higher than in low salt). Despite these similar MICs for the 3 peptides vs. *E. coli* DC2, the influence of different concentrations of these peptides on the membrane potential was quite different. The native bactenecin started to cause the release of probe at  $\frac{1}{2}$ MIC concentrations, whereas its linear derivative bac2S and reduced bactenecin showed probe release (dissipation of membrane potential) at concentration well below the MIC concentration.

#### EXAMPLE 4

The  $\alpha$ -helical and  $\beta$ -structured classes are two groups of antimicrobial polycationic peptides that have been well studied. Although their precise antimicrobial mechanism is somewhat unclear, it has been proposed that the outer and the cytoplasmic membranes of Gram negative bacteria are their primary and final targets respectively. They have been proposed to kill bacteria by first electrostatically interacting with the surface of the bacterial cytoplasmic membrane (after self promoted uptake across the outer membrane for Gram negative bacteria). Then under the influence of a membrane potential, they are proposed to insert into the membrane and form channels to leak internal constituents.

However much of this mechanism is based on data from model membrane studies.

Bactenecin belongs to a group of cationic peptides with only one disulphide bond. Bactenecin was active against the wild type Gram negative bacteria *E. coli*, *P. aeruginosa* and *S. typhimurium*, whereas the linear derivative and reduced form were relatively inactive. All three forms were equally active against outer membrane efflux defective mutants. This observation indicated that the disulphide bond was important for interaction with the outer membrane as confirmed here. Bactenecin had a better binding ability for LPS and also permeabilized the outer membrane better, explaining its better activity vs. wild type Gram negative bacteria. Computer modeling of bactenecin with InsightII software (Biosym Technologies Inc., San Diego, Calif.) indicated that bactenecin was a loop molecule with a hydrophobic ring and a positively charged face constructed from the C- and N-terminal portions of the molecule. Such a conformation, which was consistent with the CD spectral studies (Figure 1A-C), may make bactenecin a more amphipathic molecule than the unstructured linear and reduced form which exist in solution as random structures.

CD spectra indicated that bactenecin existed as a rigid  $\beta$ -turn loop molecule regardless of its environment. The molecule will thus be too small to span the membrane and form pores or channels unless a multimer is involved. Therefore it was of interest to know how this molecule interacted with the cytoplasmic membrane, which was believed to be the final target of many cationic peptides. If bactenecin interacts with the cytoplasmic

membrane, it should at a minimum make it proton-leaky, and thus dissipate the membrane potential. DiS-C3-(5) is a membrane potential dependent dye, which is released from cells when the membrane potential is disrupted, leading to fluorescence dequenching. Despite their equivalent MIC value against *E. coli* DC2, the pattern of  
5 interaction of bactenecin and its linear variants with the cytoplasmic membrane was quite different. The linear variants dissipated the cytoplasmic membrane potential at concentrations as low as 0.125 mg/ml, whereas native bactenecin had effects on membrane potential only at concentration  $\frac{1}{2}$  MIC whereas the maximal effect was only seen at 4 fold the MIC. The different conformations that these bactenecin peptides  
10 adopted when interacting with hydrophobic membranes may be responsible for these differences. Linear variants with a more flexible structure were able to interact with the inner membrane in a way different from the native bactenecin with a rigid cyclic structure.

Although the invention has been described with reference to the presently preferred  
15 embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

**WHAT IS CLAIMED IS:**

1. An isolated antimicrobial peptide having an amino acid sequence selected from the group consisting of:

RLCRIVVIRVCR	(SEQ ID NO:1);
RLARIVVIRVAR	(SEQ ID NO:2);
RLSRIVVIRVCR	(SEQ ID NO:3);
RLSRIVVIRVSR	(SEQ ID NO:4);
RRCPIVVIRVCR	(SEQ ID NO:5);
RICRIVVIRCIR	(SEQ ID NO:6);
RLCPRVRIRVCR	(SEQ ID NO:7);
KKCPIVVIRVCK	(SEQ ID NO:8);
RRRCPIVVIRVCRR	(SEQ ID NO:9);
RRRLCPIVIRVCRR	(SEQ ID NO:10);
RRLCRIVVIRVCRR	(SEQ ID NO:11);
RLCRIVPVIRVCR	(SEQ ID NO:12);
RLCRIVWVIRVCR	(SEQ ID NO:13);
RRLCRIVWVIRVCRR	(SEQ ID NO:14);
RRCPIVWVIRVCR	(SEQ ID NO:15);
RRCPIVWVIPVCRR	(SEQ ID NO:16);
RLCRIVVIRVCR	(SEQ ID NO:17);
RLCRIVVIRVCRIVIVIV	(SEQ ID NO:18); and

analogs, derivatives, amidated variations and conservative variations thereof.

2. An isolated polynucleotide which encodes a peptide of claim 1.

3. An isolated polynucleotide which encodes a peptide selected from the group consisting of:

RLCRIVVIRVCR	(SEQ ID NO:1);
RLARIVVIRVAR	(SEQ ID NO:2);
RLSRIVVIRVCR	(SEQ ID NO:3);
RLSRIVVIRVSR	(SEQ ID NO:4);
RRCPIVVIRVCR	(SEQ ID NO:5);
RICRIVVIRCIR	(SEQ ID NO:6);
RLCPRVRIRVCR	(SEQ ID NO:7);
KKCPIVVIRVCK	(SEQ ID NO:8);
RRRCPIVVIRVCRR	(SEQ ID NO:9);
RRRLCPIVIRVCRR	(SEQ ID NO:10);
RRLCRIVVIRVCRR	(SEQ ID NO:11);
RLCRIVPVIRVCR	(SEQ ID NO:12);
RLCRIVWVIRVCR	(SEQ ID NO:13);
RRLCRIVWVIRVCRR	(SEQ ID NO:14);
RRCPIVWVIRVCR	(SEQ ID NO:15);
RRCPIVWVIPVCRR	(SEQ ID NO:16);
RLCRIVVIRVCR	(SEQ ID NO:17); and
RLCRIVVIRVCRIVIVIV	(SEQ ID NO:18).

4. A method of inhibiting the growth of bacteria comprising contacting the bacteria with an inhibiting effective amount of a peptide having an amino acid sequence selected from the group consisting of:

RLCRIVVIRVCR	(SEQ ID NO:1);
RLARIVVIRVAR	(SEQ ID NO:2);
RLSRIVVIRVCR	(SEQ ID NO:3);
RLSRIVVIRVSR	(SEQ ID NO:4);
RRCPIVVIRVCR	(SEQ ID NO:5);
RICRIVVIRCIR	(SEQ ID NO:6);
RLCPRVRIRVCR	(SEQ ID NO:7);
KKCPIVVIRVCK	(SEQ ID NO:8);
RRRCPIVVIRVCRR	(SEQ ID NO:9);
RRRLCPIVIRVCRR	(SEQ ID NO:10);
RRLCRIVVIRVCRR	(SEQ ID NO:11);
RLCRIVPVIRVCR	(SEQ ID NO:12);
RLCRIVWVIRVCR	(SEQ ID NO:13);
RRLCRIVWVIRVCRR	(SEQ ID NO:14);
RRCPIVWVIRVCR	(SEQ ID NO:15);
RRCPIVWVIPVCRR	(SEQ ID NO:16);
RLCRIVVIRVCR	(SEQ ID NO:17);
RLCRIVVIRVCRIVIVIV	(SEQ ID NO:18); and

analogs, derivatives, amidated variations and conservative variations thereof.

5. The method of claim 4, wherein the bacteria is gram positive.
6. The method of claim 5, wherein the bacteria is selected from the group consisting of: *Escherichia coli*, *Pseudomonas aeruginosa*, *Enterobacter cloacae*, *Staphylococcus typhimurium*, *Staphylococcus aureus*, *Enterobacter faecalis*, *Listeria monocytogenes*, *Corynebacterium xerosis*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Streptococcus mitis* and *Staphylococcus epidermidis*.
7. The method of claim 4, wherein the bacteria is gram negative.

8. The method of claim 7, wherein the bacteria is selected from the group consisting of *E. coli*, *P. aeruginosa*, and *S. typhimurium*.
9. The method of claim 4, wherein the peptide is administered in combination with at least one antibiotic.
10. The method of claim 9, wherein the antibiotic is selected from the group consisting of aminoglycosides, penicillins, cephalosporins, carbapenems, monobactams, quinolones, tetracyclines, and glycopeptides.
11. The method of claim 10, wherein the antibiotic is selected from the group consisting of amikacin, gentamicin, kanamycin, netilmicin, tobramycin, streptomycin, azithromycin, clarithromycin, erythromycin, erythromycin estolate/ethylsuccinate/glucetate/lactobionate/stearate, penicillin G, penicillin V, methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, ampicillin, amoxicillin, ticarcillin, carbenicillin, mezlocillin, azlocillin, piperacillin, cephalothin, cefazolin, cefaclor, cefamandole, cefoxitin, cefuroxime, cefonicid, cefmetazole, cefotetan, cefprozil, loracarbef, cefetamet, cefoperazone, cefotaxime, ceftizoxime, ceftriaxone, ceftazidime, cefepime, cefixime, cefpodoxime, cefsulodin, imipenem, aztreonam, fleroxacin, nalidixic acid, norfloxacin, ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, cinoxacin, doxycycline, minocycline, tetracycline, vancomycin, chloramphenicol, clindamycin, trimethoprim, sulfamethoxazole, nitrofurantoin, rifampin and mupirocin and teicoplanin.

12. A method of inhibiting an endotoxemia or sepsis associated disorder in a subject having or at risk of having such a disorder, comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence selected from the group consisting of:

RLCRIVVIRVCR	(SEQ ID NO:1);
RLARIVVIRVAR	(SEQ ID NO:2);
RLSRIVVIRVCR	(SEQ ID NO:3);
RLSRIVVIRVSR	(SEQ ID NO:4);
RRCPIVVIRVCR	(SEQ ID NO:5);
RICRIVVIRCIR	(SEQ ID NO:6);
RLCPRVRIRVCR	(SEQ ID NO:7);
KKCPIVVIRVCK	(SEQ ID NO:8);
RRRCPIVVIRVCRR	(SEQ ID NO:9);
RRRLCPIVIRVCRR	(SEQ ID NO:10);
RRLCRIVVIRVCRR	(SEQ ID NO:11);
RLCRIVPVIRVCR	(SEQ ID NO:12);
RLCRIVWVIRVCR	(SEQ ID NO:13);
RRLCRIVWVIRVCRR	(SEQ ID NO:14);
RRCPIVWVIRVCR	(SEQ ID NO:15);
RRCPIVWVIPVCRR	(SEQ ID NO:16);
RLCRIVVIRVCR	(SEQ ID NO:17);
RLCRIVVIRVCRIVIVIV	(SEQ ID NO:18); and

analogs, derivatives, amidated variations and conservative variations thereof.

13. The method of claim 12, wherein the disorder is septic shock.
14. The method of claim 12, wherein the peptide is administered in combination with at least one antibiotic.
15. The method of claim 14, wherein the antibiotic is selected from the group consisting of aminoglycosides, penicillins, cephalosporins, carbapenems, monobactams, quinolones, tetracyclines, and glycopeptides.

16. The method of claim 15, wherein the antibiotic is selected from the group consisting of amikacin, gentamicin, kanamycin, netilmicin, tobramycin, streptomycin, azithromycin, clarithromycin, erythromycin, erythromycin estolate/ethylsuccinate/glucaptate/lactobionate/stearate, penicillin G, penicillin V, methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, ampicillin, amoxicillin, ticarcillin, carbenicillin, mezlocillin, azlocillin, piperacillin, cephalothin, cefazolin, cefaclor, cefamandole, cefoxitin, cefuroxime, cefonicid, cefmetazole, cefotetan, cefprozil, loracarbef, cefetamet, cefoperazone, cefotaxime, ceftizoxime, ceftriaxone, ceftazidime, cefepime, cefixime, cefpodoxime, cefsulodin, imipenem, aztreonam, fleroxacin, nalidixic acid, norfloxacin, ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, cinoxacin, doxycycline, minocycline, tetracycline, vancomycin, chloramphenicol, clindamycin, trimethoprim, sulfamethoxazole, nitrofurantoin, rifampin, mupirocin and teicoplanin.

17. A method of inhibiting the growth of a eukaryotic cell comprising contacting the eukaryotic cell with an inhibiting effective amount of a peptide having an amino acid sequence selected from the group consisting of:

RLCRIVVIRVCR	(SEQ ID NO:1);
RLARIVVIRVAR	(SEQ ID NO:2);
RLSRIVVIRVCR	(SEQ ID NO:3);
RLSRIVVIRVSR	(SEQ ID NO:4);
RRCPIVVIRVCR	(SEQ ID NO:5);
RICRIVVIRCIR	(SEQ ID NO:6);
RLCPRVRIRVCR	(SEQ ID NO:7);
KKCPIVVIRVCK	(SEQ ID NO:8);
RRRCPIVVIRVCRR	(SEQ ID NO:9);
RRRLCPIVIRVCRR	(SEQ ID NO:10);
RRLCRIVVIRVCRR	(SEQ ID NO:11);
RLCRIVPVIRVCR	(SEQ ID NO:12);
RLCRIVWVIRVCR	(SEQ ID NO:13);
RRLCRIVWVIRVCRR	(SEQ ID NO:14);
RRCPIVWVIRVCR	(SEQ ID NO:15);
RRCPIVWVIPVCRR	(SEQ ID NO:16);
RLCRIVVIRVCR	(SEQ ID NO:17);
RLCRIVVIRVCRIVIVIV	(SEQ ID NO:18); and


analogs, derivatives, amidated variations and conservative variations thereof.

18. The method of claim 17, wherein the eukaryotic cell is an animal cell.
19. The method of claim 18, wherein the animal cell is a neoplastic cell.
20. The method of claim 19, wherein the neoplastic cell is a glioblastoma cell.
21. The method of claim 17, wherein the peptide is administered in combination with at least one chemotherapeutic agent.


22. The method of claim 21, wherein the chemotherapeutic agent is selected from the group consisting of bleomycin, neocarcinostatin, suramin, doxorubicin, taxol, mitomycin C and cisplatin.
23. A method of inhibiting a cell proliferation-associated disorder in a subject having or at risk of having such a disorder, comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence selected from the group consisting of:
- |                    |                     |
|--------------------|---------------------|
| RLCRIVVIRVCR       | (SEQ ID NO:1);      |
| RLARIVVIRVAR       | (SEQ ID NO:2);      |
| RLSRIVVIRVCR       | (SEQ ID NO:3);      |
| RLSRIVVIRVSR       | (SEQ ID NO:4);      |
| RRCPIVVIRVCR       | (SEQ ID NO:5);      |
| RICRIVVIRCIR       | (SEQ ID NO:6);      |
| RLCPRVIRVCR        | (SEQ ID NO:7);      |
| KKCPIVVIRVCK       | (SEQ ID NO:8);      |
| RRRCPIVVIRVCRR     | (SEQ ID NO:9);      |
| RRRLCPIVIRVCRR     | (SEQ ID NO:10);     |
| RRLCRIVVIRVCRR     | (SEQ ID NO:11);     |
| RLCRIVPVIRVCR      | (SEQ ID NO:12);     |
| RLCRIVWVIRVCR      | (SEQ ID NO:13);     |
| RRLCRIVWVIRVCRR    | (SEQ ID NO:14);     |
| RRCPIVWVIRVCR      | (SEQ ID NO:15);     |
| RRCPIVWVIPVCRR     | (SEQ ID NO:16);     |
| RLCRIVVIRVCR       | (SEQ ID NO:17);     |
| RLCRIVVIRVCRIVIVIV | (SEQ ID NO:18); and |
- analogs, derivatives, amidated variations and conservative variations thereof.
24. The method of claim 23, wherein the peptide is administered in combination with at least one chemotherapeutic agent.

25. The method of claim 24, wherein the chemotherapeutic agent is selected from the group consisting of bleomycin, neocarzinostatin, suramin, doxorubicin, taxol, mitomycin C and cisplatin.

1/6

**FIG. 1A**

2/6

**FIG. 1B**

3/6




FIG. 1C

4/6




FIG. 2

5/6




FIG. 3

6/6




FIG. 4